3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Neoplasms
2
Meningioma
2
Breast Neoplasms
2
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neurofibromatosis 2
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Fallopian Tube Neoplasms
1
Estrogen Receptor Positive Breast Cancer
1
Endometrial Neoplasms
1
Disease
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Advanced Cancer
1
Adenocarcinoma
1
Interventions
vistusertib
1
proto-oncogene protein c-fes-fps
1
Transurethral Resection of Bladder
1
Hydroxychloroquine
1
Fulvestrant
1
Everolimus
1
Estrogens
1
Estradiol
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Estrogen Receptor Positive Breast Cancer
×
vistusertib
×
Clear all
NCT02216786
2024-12-02
MANTA
Queen Mary University of London
Phase 2
Completed
333 enrolled